# Ansa Biotechnologies **Source:** https://geo.sig.ai/brands/ansa-biotechnologies **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** ansabio.com **Last Updated:** 2026-04-14 ## Summary Enzymatic DNA synthesis company using TdT enzymes to write longer, higher-fidelity DNA; $68M Series B for synthetic biology and therapeutic applications. ## Company Overview Ansa Biotechnologies is a synthetic DNA synthesis company developing enzymatic DNA writing technology to overcome the length and quality limitations of chemical DNA synthesis. Founded in 2021 and headquartered in Emeryville, California, Ansa uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes rather than phosphoramidite chemistry to build DNA strands, enabling synthesis of longer sequences with higher fidelity and fewer toxic reagents. The company emerged from research at UC Berkeley and Lawrence Berkeley National Laboratory. The company raised $68 million in Series B funding in 2023, backed by investors including Data Collective (DCVC), The Engine, and Andreessen Horowitz Bio, to commercialize its enzymatic synthesis platform. Ansa's technology is particularly relevant for applications requiring long DNA fragments — synthetic biology gene construction, therapeutic oligonucleotides, and data storage — where conventional synthesis reaches length and error-rate ceilings. By 2024-2025, the company has been delivering custom DNA synthesis orders to pharmaceutical, agricultural biotech, and research customers. In 2025, Ansa Biotechnologies operates at a critical juncture in synthetic biology infrastructure, as the field requires DNA synthesis capabilities far exceeding what chemical methods can reliably deliver. The company competes with Twist Bioscience, Integrated DNA Technologies (IDT), and emerging enzymatic competitors like DNA Script. Ansa's 2025-2026 priorities include scaling throughput, pursuing FDA engagement for therapeutic oligonucleotide applications, and expanding into DNA data storage partnerships where unprecedented sequence lengths are commercially valuable. ## Frequently Asked Questions ### What is Ansa Biotechnologies? Ansa Biotechnologies is a DNA synthesis company that revolutionizes how scientists access synthetic DNA through proprietary enzymatic synthesis technology. Founded in 2018 and based in Emeryville, CA, the company enables faster, longer, and more accurate DNA production than traditional methods. ### What products and services does Ansa Biotechnologies offer? Ansa offers enzymatic DNA synthesis, ultra-long DNA constructs up to 50 kb, synthetic DNA manufacturing, and gene synthesis services. The company is the industry's first to offer guaranteed on-time DNA delivery. ### Who are Ansa Biotechnologies' target customers? Ansa Biotechnologies serves scientists and researchers who need synthetic DNA for their work. The company provides DNA synthesis solutions for customers requiring constructs ranging from standard genes to ultra-long 50 kb sequences. ### When was Ansa Biotechnologies founded? Ansa Biotechnologies was founded in 2018. The company participated in Y Combinator's Winter 2020 batch (W20). ### Where is Ansa Biotechnologies located? Ansa Biotechnologies is headquartered in Emeryville, California. ### How much funding has Ansa Biotechnologies raised? Ansa has raised $137 million in total funding. This includes a $68 million Series A in April 2022 led by Northpond Ventures and a $54.4 million Series B in September 2025 led by Cerberus Ventures, with additional investors including Fall Line Capital, AIM13, and Black Opal. ### What are Ansa Biotechnologies' key achievements? Ansa launched its first commercial products in July 2024 and is the industry's first company to offer guaranteed on-time DNA delivery. In May 2025, the company introduced a 50 kb Ultra-Long DNA early access program, offering constructs up to 50 kb in under four weeks. ### What technology does Ansa Biotechnologies use? Ansa uses proprietary enzymatic synthesis technology for DNA production. This approach enables faster, longer, and more accurate DNA synthesis compared to traditional chemical synthesis methods. ### How can I access Ansa Biotechnologies' Ultra-Long DNA products? Ansa launched a 50 kb Ultra-Long DNA early access program in May 2025. The program offers DNA constructs up to 50 kb with delivery in under four weeks. ### What are the latest developments at Ansa Biotechnologies? Most recently, Ansa closed a $54.4 million Series B funding round in September 2025 led by Cerberus Ventures. The company also introduced its 50 kb Ultra-Long DNA early access program in May 2025, following the launch of its first commercial products in July 2024. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*